WHO greenlights the world's first malaria vaccine — but it's not a perfect shot
It's also the first vaccine against a parasitic disease in humans. But there are issues to consider, from its rate of effectiveness to the dosage schedule.
The world's arsenal against malaria just got a fancy new bazooka. But it's not the easiest weapon to deploy, it only hits its target 30 to 40% of the time, and it's not yet clear who's going to pay for it.
The weapon in question is the RTS,S vaccine from GlaxoSmithKline, which on Wednesday got the green light from the World Health Organization for
